J&J device revenue jumped 6.4% in 2012 thanks to Synthes buy

Johnson & Johnson ($JNJ) paid a pretty penny for orthopedics giant Synthes, but last year's $21.3 billion acquisition made quite a mark on the company's annual report, as J&J posted 6.4% revenue growth in its devices division and a 34.3% jump in its ortho business.

However, Synthes' contributions also helped dull the effect of weakening results in J&J's other device business, including a 13.2% drop in cardiovascular revenue and a 4.4% slump in diagnostics in 2012.

For the year, J&J pulled in $27.4 billion from its device and diagnostics unit, and the company's total revenue clocked in at $67.2 billion, a 3.4% increase over 2011. The company charted growth in specialty surgery (7.2%) and vision care (2.7%), but its diabetes and surgical units posted declines on the year.

J&J's fourth-quarter results tell mostly the same story: Vascular, diabetes and diagnostics all declined compared to the previous year, but orthopedics grew 64.3%, enough to pace a 13.7% quarterly jump for the the whole segment.

And then there's the cost of recalls. In the fourth quarter alone, J&J took about $800 million in charges largely blamed on litigation and associated costs for its recalled ASR all-metal hip implants, and the company is now being dragged into court over its other hip implant, the Pinnacle.

At the same time, last year marked a milestone for J&J's devices and diagnostics: The business has become the company's largest unit, outpacing pharma by more than $2 billion in revenue. Furthermore, the business' 6.4% growth beat the drug unit's 4% jump and the consumer segment's 2.9% decline. That spike is also largely due to the Synthes buy, as integrating the new business accounted for 3.1% of the company's total sales growth across all units.

- read J&J's release
- check out the full results (pdf)

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.